Literature DB >> 998853

Clinical evaluation of 99mTc-pyridoxylideneglutamate for hepatobiliary scanning.

N M Matolo, R C Stadalnik, E F Wolfman.   

Abstract

Clinical evaluation of hepatobiliary scanning using 99mTc-PG was done in twenty normal volunteers and eighty-three patients with liver and biliary tract disease. Satisfactory images of the biliary tract were obtained using small dosages of this agent. In normal humans, the agent reached the liver in 5 minutes, and the common bile duct, gallbladder, and duodenum in 10 to 20 minutes. The gallbladder was not visualized when the cystic duct was obstructed in patients with acute and chronic cholecystitis. In patients with partial common bile duct obstruction, a distended duct was visualized and there was delay in transit of radioactivity into the duodenum. With complete common bile duct obstruction, no radioactivity was seen in the biliary or gastrointestinal tracts up to 24 hours after injection. Hepatocellular disease was characterized by delayed liver clearance and delayed visualization of the biliary and gastrointestinal tracts. There were no toxic or other untoward effects in any patients.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 998853     DOI: 10.1016/0002-9610(76)90442-6

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  3 in total

1.  A prospective study of radionuclide biliary scanning in acute pancreatitis.

Authors:  J P Neoptolemos; D P Fossard; J M Berry
Journal:  Ann R Coll Surg Engl       Date:  1983-05       Impact factor: 1.891

2.  Nonvisualization of the gallbladder by 99mTc-HIDA cholescintigraphy as evidence of cholecystitis.

Authors:  P Paré; E A Shaffer; L Rosenthall
Journal:  Can Med Assoc J       Date:  1978-02-18       Impact factor: 8.262

3.  A comparative study of intravenous cholangiography and 99mTc-pyridoxylideneglutamate in patients with hepatobiliary disease.

Authors:  R C Stadalnik; C J Rosenquist
Journal:  Gastrointest Radiol       Date:  1977-10-25
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.